Candel Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 42
- Market Cap
- -
- Website
- http://www.candeltx.com
- Introduction
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04495153
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸UConn Health, Farmington, Connecticut, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas
- Conditions
- Glioma, Malignant
- Interventions
- Radiation: RadiationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03576612
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Biological: CAN-2409 + valacyclovir
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03131037
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT02768363
- Locations
- 🇺🇸
Foothills Urology, Golden, Colorado, United States
🇺🇸Jesse Brown VA Medical Center, Chicago, Illinois, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Candel Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02446093
- Locations
- 🇺🇸
Lee Health/Regional Cancer Center, Fort Myers, Florida, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
- Prev
- 1
- 2
- 3
- Next